Performance-Driven Payments in Europe - Payment of high-priced drugs in the UK, BeNeLuxAI, Italy and Germany

The German draft drug law GSAV foresees registries for orphan drugs; first performance-driven payment contracts have already been established. Other countries, such as Italy, have used this pricing model for quite some time.
-
This conference compiles Europe's various tendencies in regard to the payment of high-priced innovative drugs, which are about to enter the European market.
-
After attending this meeting, you will be aware of the existing payment models and be knowledgeable about the upcoming payment trends in Europe. Lastly, you will get to know possibilities you have in the direct contraction situation with payers.